Article taken from: finance.yahoo.com
Peter Lynch Chart of BLPH According to Bellerophon, the FDA’s decision immediately makes the company’s delivery system available for use at high doses in ventilated Covid-19 patients, according to an article in FierceBiotech. Bellerophon has been studying its use to prevent potentially damaging high blood pressure in the lungs among patients with chronic pulmonary diseases. The compound has also been tested as a possible treatment for a strain of SARS, the respiratory virus that was first identiified in China 17 years ago. […] Given the growing demand for ventilators to treat the increasing number of Covid-19 patients, the Bellerophon system could play a key role in the fight against the virus. […] In 2015, Bellerophon’s lead product, a bioresorbable cardiac matrix for heart attack patients, failed in a phase 3 study.
Click here to read the full article